ArticleJournal of virology2025
Retinal transduction profiling of diverse AAV serotypes via intravitreal injection.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A novel adeno-associated viral vector derived from human spleen isolate AAV.hu.S17.Journal, genetic engineering & biotechnology · 2026Article
- Functional In Vitro Assessment of rAAV-Delivered Retinol Dehydrogenase 12 (RDH12) Activity.International journal of molecular sciences · 2026Article
- Gene replacement therapy for Piga GPI-anchor deficiency in the developing nervous system.bioRxiv : the preprint server for biology · 2025Article
- Tunable dual-AAV sparse labeling of PVFrontiers in neural circuits · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Optimizing adeno-associated virus (AAV) capsid and dosing selection is critical for the clinical translation of retinal gene therapy. This study aims to provide a comprehensive reference by comparing the transduction efficiency, cellular tropisms, and temporal retinal expression patterns of various AAV serotypes for intravitreal retinal gene therapy. A series of AAV vectors were intravitreally injected into C57BL/6J mice. Retinal tissues were harvested 4 weeks post-injection to evaluate the transgene expression and cellular tropisms by immunostaining. Both ssAAV2.NN and scAAV2.NN vectors at a dose escalation were administered, with similar assessments conducted at 2 and 4 weeks post-injection. Additionally, the early-phase retinal transduction profiles of AAV vectors were detected at multiple time points within 12 weeks following administration. Stronger green fluorescent protein (GFP) fluorescence was observed in retinas intravitreally transduced with AAV2.NN, AAV2.GL, and AAV8 vectors, with AAV2.GL showing greater co-localization with GS IMPORTANCE: The retinal transduction efficiency and cellular tropisms of serial AAV serotypes, including AAV2, AAV2.7m8, AAV2.NN, AAV2.GL, AAV8, AAV11, and AAV.SPR, were simultaneously and unbiasedly quantified and compared following intravitreal injection. Transgene fluorescence was detectable in cells as early as 3 days post-injection in retinas intravitreally transduced with both ssAAV2.NN and scAAV2.NN vectors. The timeliness of the onset and level of transgene expression in retinas intravitreally transduced with ssAAV2.NN and scAAV2.NN vectors were characterized during the early phase post-injection. Differences in retinal transduction efficiency and cellular tropisms of scAAV2.NN vectors at varying doses via intravitreal injection are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.